transcripts

TRANSCRIPT, Meeting 9, Session 3

DR. GUTMANN:  So we will hear now from Dr. John Parker.  Welcome.

          John Parker is Chair of the National Biodefense Science Board.  Dr. Parker is also the Senior Vice President of Corporate Development, Chief Medical Officer, Chairman of the Institutional Review Board, and Technical Fellow at Science Applications International Corporation.

Date

Thu, 05/17/2012

TRANSCRIPT, Meeting 9, Session 7

DR. WAGNER:  Greg Biggers and Leonard D'Avolio, if you would join us up here?

                        DR. GUTMANN:  Thank you all.  I think members of the Commission will be soon seated.  So I'll start with my introduction.

                        Continuing on genomic privacy and data access, Greg Biggers, welcome, serves on the Council for Genetic Alliance, which is a leading non‑profit health advocacy organization committed to transforming health through genetics.  And Mr. Biggers is representing Council for Genetic Alliance here today.

Date

Thu, 05/17/2012

TRANSCRIPT, Meeting 9, Session 6

Dr. Wagner: We're switching gears to an entirely different project.  And that is the work we've been doing on privacy and access to whole genome sequence data.  We began this last year, had another effort, continued our deliberations in San Francisco in February, and today we're going to revisit the topic of privacy and start a discussion about the right to privacy in both theory and practice.

Date

Thu, 05/17/2012

TRANSCRIPT, Meeting 9, Session 5

DR. GUTMANN:  We're missing Lisa and John, so we'll wait a minute.  Okay.  I assume ‑‑ do we know where two of our panelists are?  Well, we will just ‑‑ we'll get started.

Date

Thu, 05/17/2012

TRANSCRIPT, Meeting 9, Session 4

DR. WAGNER:  Will Professor Hodge and Doctors Taylor and Kaplowitz please come forward?

                        As they're grabbing their seats, this next section is one where we'll discuss special ethical considerations that arise in medical countermeasure research and use.

                        Speaking to us first is Dr. Lisa Kaplowitz.  Welcome.

Date

Thu, 05/17/2012

TRANSCRIPT, Meeting 9, Session 2

DR. WAGNER:  And Drs. Anderson and Klein, if you could join us?

                        Welcome to you both.  This session, as Amy said, focuses on pediatric research and practice, benefits as well as some of the practical challenges that it poses, and we will hear first from Dr. Michael Anderson here on behalf of the American Academy of Pediatrics, Vice President and Chief Medical Officer for University Hospital's Case Medical Center, and Associate Professor of Pediatrics at Case Western Reserve School of Medicine in Cleveland.

Date

Thu, 05/17/2012

TRANSCRIPT, Meeting 9, Session 1

DR. GUTMANN:  Thank you.  Could I invite our first presenters up to the table, please, and thank you all for being here.  I thank you, before we get to ask you the hard questions, which you then may not thank us for being here.

                        We're going to begin our day with the discussion of Special Considerations for Research on Children because that's the fundamental issue that leads us to be dealing with this charge and we have with us Dr. David DeGrazia, who's a Professor of Philosophy at George Washington University.  Welcome, David.

Date

Thu, 05/17/2012

TRANSCRIPT, Meeting 9, Opening Remarks

DR. GUTMANN:  Good morning, everybody.  I'm Amy Gutmann.  I'm President of the University of Pennsylvania and I have the privilege of serving as Chair of the Presidential Commission for the Study of Bioethical Issues, and I welcome you all here this morning.

                        On behalf of myself and our Vice‑Chair Jim Wagner, who will say a few words in a minute, I would like to welcome you.  This is our ninth meeting of the Presidential Commission and we have some important work to do.

Date

Thu, 05/17/2012

TRANSCRIPT, Meeting 8 Session 2

DR. GUTMANN:  So, we're off to a great start, and now, we're turning our attention to discussing directly, questions of individual privacy and the public good, and I emphasize both, individual privacy and the public good, as they relate to whole genome sequencing, and we've already had hints of this issue in our earlier session.

Date

Thu, 02/02/2012

TRANSCRIPT, Meeting 8 Session 6

DR. GUTMANN:  Good morning, everybody.  I'm Amy Gutmann.  I am Chair of the Presidential Commission for the Study of Bioethical Issues and President of the University of Pennsylvania, and my Vice Chair, Jim Wagner, who is President of Emory University will lead off this morning's session, but let me just do a few preliminary things, if I may.

Date

Fri, 02/03/2012

Pages

Subscribe to RSS - transcripts